4
The effects of radiation therapy pose significant challenges in breast reconstruction as a result of the damage done to chest wall tissue. In general, there is agreement that implant reconstruction exposes irradiated patients to comparatively higher associated morbidity compared with nonirradiated patients. 6, 7 It is also generally accepted that autologous flaps for breast reconstruction offer the advantage of replacing radiation-exposed breast and chest wall tissue with arguably superior outcomes. [8] [9] [10] However, the clear recent trend in favor of implant breast reconstruction in irradiated patients suggests that proponents believe that success rates, aesthetic outcomes, and patient satisfaction are reasonable with this option. This view is supported in the literature. 7, [11] [12] [13] Although several studies show failure rates up to 45 percent among irradiated patients with implant reconstruction, other studies have reported considerably better outcomes. [11] [12] [13] This divergence in published literature indicates that more information would be beneficial in the debate about reconstructing the irradiated breast, especially for patients with no contraindications to all available reconstruction options.
In the current health care reform dispensation that emphasizes alternative payment models to achieve cost containment, a useful metric to add to the debate about reconstruction of the irradiated breast is the relative use of health care resources between options. Thus, the high failure and morbidity rates widely reported with implant reconstruction in irradiated patients warrant examination from the cost perspective. We used nationwide longitudinal data to examine health care resource use associated with two different methods of breast reconstruction: implant and autologous reconstruction. We hypothesized that, among irradiated breast cancer patients, failure rates would be higher with implant reconstruction. In addition, failure rates would contribute the most to higher average cumulative cost with either reconstruction method.
PATIENTS AND METHODS

Data Source and Study Cohort
We The first inclusion criterion was claims for radiation therapy associated with breast cancer diagnosis. (See Appendix, Supplemental Digital Content 1, which shows the diagnosis and procedure codes for breast cancer, breast reconstruction, and radiation therapy, http://links.lww.com/ PRS/C156.) Second, selected patients had medical claims for mastectomy and breast reconstruction procedures also associated with breast cancer diagnosis between January 1, 2009, and December 31, 2012. This period allowed a 24-month followup for each patient, enabling us to capture health care encounters and the associated use of health care resources following the index reconstruction procedure. Other inclusion criteria were female sex, age 18 years or older, and continuous enrollment for at least 24 months after the index procedure. To simplify our comparisons, we included patients who had implant-only or autologousonly procedures and excluded those who had a combination of both autologous and implant techniques in the index reconstruction episode (e.g., implants or tissue expanders with a latissimus dorsi flap). We used International Classification of Diseases, Ninth Revision codes and Current Procedural Terminology codes to identify specific diagnoses and procedures, respectively (see Appendix, Supplemental Digital Content 1, http:// links.lww.com/PRS/C156).
Components of Health Care Resource Use
For each patient, we delineated components of health care resource use in the longitudinal course of breast reconstruction over the 24-month follow-up period and tallied the costs (i.e., reimbursements from payers associated with each component). [14] [15] [16] These components included the following: (1) the index procedure of reconstruction (e.g., initial autologous reconstruction procedure or tissue expander placement) (see Appendix, Supplemental Digital Content 1, http://links.lww.com/PRS/C156); (2) 
Analyses
We described socioeconomic, demographic, and clinical variables in the study population according to reconstruction type (implant/autologous). We also included the five above-listed components of health care resource use in the descriptions by reconstruction type (Table 1) . Second, examining each group of reconstruction type in aggregate, we calculated the percentage contribution of each of the five components of health care resource use to the cumulative cost of reconstruction ( Fig. 1) .
Then, we used generalized linear models stratified by reconstruction type to evaluate the association between reconstruction failure (key predictor variable) and the cumulative cost of reconstruction [i.e., the tally of the five components of health care resource use (dependent variable)] ( Table 2 ). The generalized linear models eliminate the requirement for a normal distribution of one response variable (i.e., cost) for proper model fitting. From these models, we predicted the mean adjusted cumulative costs for implant and autologous patients. We also predicted the adjusted cumulative costs for patients with complications, readmissions/emergency department visits, and reconstruction failures for each type of reconstruction ( Table 2) . We ran an additional stratified linear model consisting of failed implant patients with the cumulative cost of reconstruction as the dependent variable and the method of subsequent reconstruction (autologous versus nonautologous) as the main predictor (Table 3) . From this model, we predicted the adjusted cumulative cost for failed implant patients who required subsequent autologous reconstruction (Table 3) . There was no need to run such a model for autologous patients because, in irradiated patients who failed autologous reconstruction, subsequent reconstruction is usually autologous. Therefore, the cumulative cost of subsequent reconstruction is reflected in the stratified model for autologous patients.
RESULTS
There were 2964 patients who met the inclusion criteria for the study. Seventy-eight percent (n = 2306) underwent implant reconstruction and 22 percent (n = 658) underwent autologous reconstruction. Table 1 shows the social, demographic, and clinical characteristics of patients by reconstruction type (implant/autologous). Twenty percent of implant patients had one reconstruction failure and 12 percent had two or more failures; these categories for autologous patients 281 (12) 10 (2) ED, emergency department. *n = 2964.
were 4 percent and 1 percent, respectively. Finally, 37.5 percent of implant failures (12 percent of all implant patients) had subsequent reconstruction by the autologous method. Figure 1 shows that in the autologous reconstruction group, the index reconstructive procedure contributed most (approximately 65 percent) to the cumulative cost of reconstruction, Plastic and Reconstructive Surgery • June 2017
and failures contributed less than 5 percent to the cumulative cost. In the implant reconstruction group, readmissions contributed the most (approximately 25 percent) to the cumulative cost and failures contributed greater than 20 percent to the cumulative cost (Fig. 1) . Tables 2 and 3 show the results of the linear regression models described in the Patients and Methods section and the adjusted predicted mean cumulative costs associated with key independent variables (linear regression Tables 2 and 3 (Tables 2 and 3 ) with a full complement of independent variables, http://links.lww. com/PRS/C159.] The unadjusted mean cumulative cost regardless of failure for implant reconstruction was $22,868. For autologous patients, the unadjusted mean cumulative cost regardless of failure was $30,527. For implant reconstruction patients with no failures (68 percent of all implant patients), the adjusted mean cumulative cost was $14,284. For autologous reconstruction patients with no failures (95 percent of all autologous patients), the adjusted mean cumulative cost was $29,199. When we examined implant reconstruction patients with failures in a stratified analysis (32 percent of all implant patients), patients who did not have subsequent autologous reconstruction (20 percent of all implant patients) had an adjusted mean cumulative cost of $23,090, and for those who had subsequent autologous reconstruction (12 percent of all implant patients), the adjusted mean cumulative cost was $47,214. Lastly, the adjusted mean cumulative cost was $48,344 for autologous patients who had failures with subsequent reconstruction (5 percent of all autologous patients).
DISCUSSION
In this study, we examined a national sample of breast cancer patients who received radiation therapy as part of their treatment along with reconstruction with implant or autologous methods. We studied their breast reconstruction course, longitudinally tracking use of health care resources reflected in reimbursements made by payers and patient out-of-pocket payments.
First, the results of the study agree with existing literature that implant reconstruction is more common in irradiated patients. [3] [4] [5] Seventy-eight percent of patients who met inclusion criteria underwent implant reconstruction as the index attempt at breast reconstruction. Second, using these nationwide longitudinal data, the results also demonstrate a failure rate of implant reconstruction in irradiated patients within the ranges reported in previous studies. 13, 17, 18 On average, implant-based breast reconstructions were less expensive than autologous breast reconstructions (unadjusted mean cumulative cost, $22,868 versus $30,527). However, the study results demonstrate that aggregately, among irradiated patients who undergo implant reconstruction, reconstruction failures contribute over four times as much to the cumulative cost of reconstruction (>20 percent) compared with the cost of failures among patients undergoing autologous reconstruction (<5 percent) (Fig. 1) . Finally, our results show that the majority of patients in each group (implant, 68 percent; autologous, 95 percent) underwent reconstruction without failure. Costs for implant and autologous reconstruction in patients without failures were $14,284 and $29,199, respectively. Implant failure that requires autologous reconstruction cumulatively costs $47,214 per patient, and autologous failure cumulatively costs $48,344 per patient. Considering that 12 percent of implant patients compared to 5 percent of autologous patients required subsequent autologous reconstruction after failure, the total costs of failures extrapolated to the population were $13 million and $2 million, respectively. Even with the substantial evidence-including results from this study-demonstrating superior success rates with autologous reconstruction in irradiated patients, [8] [9] [10] one must acknowledge that not all irradiated patients are candidates for autologous breast reconstruction. Arguably, then, the debate about appropriate choices in irradiated breast reconstruction should be centered on patients who are candidates for all breast reconstruction options, including implant and autologous methods. Generally, studies on reconstruction of the irradiated breast do not address the reasons or indications for implant reconstruction in the cohorts studied, and this study is no exception to that trend. However, a few studies in the literature and the results from this study highlight that at least roughly one in 10 patients who undergo implant reconstruction and had a failure underwent a subsequent reconstruction with an autologous component. 9, 18 This finding indicates that autologous reconstruction was a possible initial option for these patients. According to the results from this study, one can argue that these patients potentially incurred excess reconstruction cost. The mean adjusted cost for 95 percent of the patients who underwent successful autologous reconstruction on the index attempt was $29,199 compared with $47,214 for the 12 percent of implant reconstruction patients who had failures and underwent subsequent reconstruction with an autologous component. The potential excess reconstruction cost ($18,015 per patient, for a total of $13 million) stems from the possibility that most of these patients could have undergone successful autologous reconstruction on the index attempt.
One of the most heralded components of the recent health care reform agenda is cost containment through payment reforms, with much emphasis on alternative payment models such as bundled payments (i.e., global payments for episodes of care). 19 Typically, with alternative payment models arrangements, providers (hospitals/ physicians) share in the financial risks for costs that overrun the allotted payment for episodes of care. 19 Clearly, health care resource use and their associated costs can make up only part of the equation in the choice regarding breast reconstruction among irradiated patients who have both implant and autologous options available to them. There is informed patient preference (e.g., irradiated patients aware of the increased risk of morbidity and failure with implant reconstruction that choose to undergo implant reconstruction for individual reasons). Moreover, other factors such as the growing concentration of surgeons with expertise in autologous reconstruction in fewer centers may also contribute to limiting the options some irradiated patients have. 16 Lastly, surgeon preferences play a considerable role. Studies have objectively shown a reimbursement-to-effort ratio that favors implant reconstruction compared with autologous reconstruction and plastic surgeons admitting a preference for implant reconstruction because of this favorable reimbursement-toeffort ratio. 20, 21 However, some findings from this study, such as the aggregately higher contribution of failures (>20 percent) to the mean cumulative cost of implant reconstruction in irradiated patients and the potential excess cost of implant failures in irradiated patients that subsequently undergo autologous reconstruction, are typical of factors with which providers will increasingly have to grapple. These factors will increasingly figure in decisions about how best to deploy health care resources to achieve successful outcomes for patients in a dispensation where cost containment features prominently in health care delivery.
There were some limitations in our methods. The components of health care resource use for breast reconstruction that we used in estimating cumulative costs in this study are not standardized. Moreover, there are no standard methods, to our knowledge, for estimating health care resource use and the associated costs for breast reconstruction. However, from our clinical knowledge of the course of breast reconstruction and with methods from previous related studies, we created an exhaustive list of potential uses of health care resources in the course of breast reconstruction (see Appendix, Supplemental Digital Content 2, http://links.lww.com/PRS/C157; see Appendix, Supplemental Digital Content 3, http://links.lww. com/PRS/C158) to provide reasonable estimates of cumulative cost. [14] [15] [16] In addition, as is commonly the case with secondary data from claims and administrative databases, we do not have variables that definitively describe patient or surgeon factors that influence decision-making. However, this study was less about the appropriateness of the method used for reconstruction of the irradiated breast and more an attempt to highlight what the relative resource use was for each method, to add to current knowledge on the subject. Finally, it was not possible to determine a range of failure rates and costs based on individual providers, as providers are not uniquely designated in the database. We reported national average failure rates, meaning that some providers will have higher and others lower failure rates that would be reflected in costs accordingly. However, the average failure rates we reported are well within the range reported in the literature.
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CONCLUSIONS
Our results demonstrate that implant reconstruction is much more widely used in irradiated breast cancer patients than autologous methods. Implant reconstructions are on average less expensive than autologous reconstructions. Among the irradiated patients studied, however, implant reconstruction was associated with significantly higher rates of failures compared with autologous methods, with more than one in 10 patients who underwent implant reconstruction requiring a flap for failure. Although failures resulted in substantially more health care resource use in both autologous and implant-based reconstruction, the added cost incurred was six times more among the patients with implant-based reconstruction compared with patients who underwent autologous reconstruction, a reflection of the significant difference in the respective failure rates. These findings make a case for autologous reconstruction being primarily considered in irradiated patients who have this option available.
